Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring, announces that it has been selected to participate in a programme evaluating products and clinical interventions in real-world settings at Premier Healthcare Alliance hospitals.
Premier is a performance improvement alliance of more than 2,500 U.S. hospitals which account for circa 30% of US hospital discharges. Premier, whose mission is to use the power of collaboration to lead the transformation to high quality, cost-effective care, is owned by those hospitals and other health systems.
QUEST is a voluntary collaborative consisting of 293 US hospitals nationwide that share data and best practices, while identifying and implementing opportunities for improvement to achieve top performance levels. The Quest charter member hospitals estimate that in three years they have prevented circa 25,000 deaths and reduced healthcare spending by nearly $4.5 billion.
Premier's QUEST® Comparative Effectiveness & Innovation Program ("QCEIP") helps the healthcare community better understand patient outcomes associated with the use of certain products. It consists of the following:
- Conducting a study that will correlate health outcomes to product performance using Premier's secondary data sources;
- Creating an abstract for publication based on the results of the secondary data analysis; and
- After clearing the peer review process, using a variety of communications channels to inform the Premier alliance and broader healthcare community of the study results.
The programme leverages data from the USA's most comprehensive repository of clinical, financial and outcomes information to test, validate and substantiate the concepts submitted by suppliers. Deltex Medical was selected for this project along with Baxter International and Nihon Kohden.
Bill Zeruld, vice president of Premier Research Services commented: "Testing products and clinical interventions in real-world settings is essential to ensure that safe, reliable and cost-effective care is delivered to every patient. In collaborating with these suppliers and Premier alliance hospitals, we can accelerate patient access to the most innovative and efficient products and technologies."
Ewan Phillips, Deltex Medical's chief executive, commented: "Being selected to work with Premier on the QUEST Comparative Effectiveness & Innovation Program creates a major opportunity for Deltex Medical. We expect to be able to demonstrate and then promote the value of CardioQ-ODM within a collaboration of some of the USA's leading hospitals, including some of our existing accounts. Success has the potential to accelerate the wide-scale adoption of CardioQ-ODM in the USA."